Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 28, 2018 01:00 ET | Source: ObsEva SA

ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes

Geneva, Switzerland and Boston, MA – November 28, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
November 08, 2018 01:15 ET | Source: ObsEva SA

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase 2b EDELWEISS clinical trial of linzagolix in endometriosis supports 75mg...
November 07, 2018 01:30 ET | Source: ObsEva SA

ObsEva SA to Participate in November Investor Conferences

Geneva, Switzerland and Boston, MA – November 7, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
October 31, 2018 02:30 ET | Source: ObsEva SA

ObsEva SA to Hold Third Quarter 2018 Financial Results and Business Update Call on November 8, 2018

Geneva, Switzerland and Boston, MA –October 31, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of...
October 09, 2018 16:15 ET | Source: ObsEva SA

ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting

Abstract featuring-IMPLANT2 data awarded Prize Paper by Society for Assisted Reproductive Technology (SART) Nolasiban treatment shown to significantly increase Live Birth Rate (LBR) in...
October 05, 2018 01:00 ET | Source: ObsEva SA

ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018

Recipient of Prize Paper Award from the Society for Assisted Reproductive Technology (SART) Geneva, Switzerland and Boston, MA - October 5, 2018- ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a...
October 03, 2018 01:00 ET | Source: ObsEva SA

ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)

Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment Nolasiban safety profile not different from placebo in IMPLANT 2 European MAA submission...
September 28, 2018 01:00 ET | Source: ObsEva SA

Final results of ObsEva SA Phase 2b EDELWEISS trial of Linzagolix show sustained efficacy and Bone Mineral Density safety, for the treatment of endometriosis-associated pain

Linzagolix overall efficacy and safety maintained or improved at week 24 Linzagolix 75mg once daily showed no clinically significant impact on Bone Mineral Density (BMD), supporting further...
August 28, 2018 01:30 ET | Source: ObsEva SA

ObsEva SA to Participate in September Investor Conferences

Geneva, Switzerland and Boston, MA – August 28, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
August 10, 2018 01:30 ET | Source: ObsEva SA

ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 14-15, 2018

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...